生命科学资讯

Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show

Lux Capital raises $1.5B for its ninth fund

FDA in 2025 holds fewest number of adcomms since the pandemic

Post-Hoc Live Jan. 8: Fewer drugs, more chaos — a year under the new FDA

BridgeBio shares KRAS data; Hutchmed's Phase 3 success in China

Poplar Therapeutics gets $50M Series A for immunology ambitions

GSK, Ionis say they may have a cure for some hepatitis B patients after Phase 3 win

Lilly partners with protein mapping startup InduPro for up to $950M

Rakuten Medical raises $100M for photoimmunotherapy platform

Soley emerges with $200M Series C and broad pipeline for 'stress clock'

Meanwell and Maraganore get $80M for cardio prevention biotech Corsera

Cancer biotech Disco lines up Amgen as first pharma partner

Relation, Deerfield to form new companies from discovered drug targets

Drugmakers frustrated by vaccine schedule overhaul

Jazz and Zymeworks spell out HER2 bispecific win

FDA report claiming Covid vaccine link to children's deaths misses deadline

J&J plans late-stage trial for lupus candidate after Phase 2 success

Bright Minds' shares soar on positive Phase 2 seizure reduction data

Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval

Amgen to acquire Dark Blue Therapeutics for up to $840M